Alzheimer ve Psikofarmakolojik Tedavi İlkeleri
Özet
Alzheimer Hastalığı (AH), demans vakalarının yaklaşık %75’ini oluşturan, amiloid-β proteinlerinin birikimi ve hiperfosforile tau proteinlerinin nörofibriler yumaklar (NFY) oluşturmasıyla karakterize ilerleyici bir nörodejeneratif süreçtir. Tarihsel süreçte Alois Alzheimer’ın 1901’deki klinik gözlemlerinden günümüze kadar tanı kriterleri gelişmiş; 1984’teki NINCDS-ADRDA kriterleri yerini biyobelirteçleri de kapsayan 2011 NIA-AA ve DSM-5 kriterlerine bırakmıştır. Yaşın en büyük risk faktörü olduğu bu hastalıkta, küresel yaşlanma ile birlikte ekonomik ve sosyal yük giderek artmaktadır. Günümüz tedavisinde semptomatik iyileşme sağlayan iki temel grup ilaç FDA onaylıdır: Asetilkolin Esteraz İnhibitörleri (Donepezil, Rivastigmin, Galantamin) ve NMDA reseptör antagonisti olan Memantin. Kolinerjik iletimi güçlendiren ve glutamat nörotoksisitesini azaltan bu ilaçlar yaşam kalitesini artırsa da hastalığın ilerlemesini durduramamaktadır. Bu nedenle, patofizyolojiyi doğrudan hedefleyen beta/gama sekretaz inhibitörleri, anti-agreganlar ve pasif/aktif immünizasyon yöntemlerini içeren anti-amiloid ile tau proteinini hedef alan yeni nesil tedavi arayışları ve klinik faz çalışmaları yoğun şekilde devam etmektedir.
Alzheimer's Disease (AD) is a progressive neurodegenerative process constituting approximately 75% of all dementia cases, characterized by the accumulation of amyloid-β proteins and the formation of neurofibrillary tangles (NFTs) by hyperphosphorylated tau proteins. Since Alois Alzheimer's initial clinical observations in 1901, diagnostic criteria have evolved; the 1984 NINCDS-ADRDA criteria have been replaced by the 2011 NIA-AA and DSM-5 criteria, which now incorporate biomarkers. With aging as the primary risk factor, the economic and social burden of AD is escalating globally alongside an aging population. Two main classes of drugs providing symptomatic relief are currently FDA-approved for treatment: Acetylcholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine) and the NMDA receptor antagonist Memantine. Although these medications, which enhance cholinergic transmission and mitigate glutamate neurotoxicity, improve the quality of life, they cannot halt disease progression. Consequently, novel therapeutic avenues and clinical trials directly targeting the pathophysiology—including beta/gamma-secretase inhibitors, anti-aggregants, passive/active immunization methods for anti-amyloid therapies, and tau-targeting agents—are extensively ongoing.
Referanslar
Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Zentralbl Nervenh Psych, 1907;(18):177–9.
Qiu C, Kivipelto M, Von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention.Dialogues in Clin Neurosci, 2009;11(2):111–28.
Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press; 2021.
Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nature Reviews. Drug Discovery, 2011;10(9):698–712.
Weller J, Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Research. F1000 Faculty rev. 2018 (7):1161.
Cipriani G, Dolciotti C, Picchi L, et al. Alzheimer and his disease: a brief history. Neurol Sci. 2011;32(2):275–9.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):263–9.
Naumann JP. Novel Advances in Alzheimer’s Disease. Downt Rev, 2015;1(2):3.
Association AP: Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub; 2013.
Apostolova LG. Alzheimer Disease. Continuum (Minneap Minn), 2016;22(2):419–34.
Ertekin A, Demir R, Özdemir G, et al. An Investigation of the Risk Factors and Prevalence of Alzheimer’s Disease in the Eastern Region of Turkey. Eur J Gen Med, 2015.
Grossberg GT, Tong G, Burke AD, et al. Present Algorithms and Future Treatments for Alzheimer’s Disease. J Alzheimer’s Dis, 2019;67:1157–71.
Zhang X-X, Tian Y, Wang Z-T, et al. The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J Prev Alzheimer’s Dis, 2021;8(3):313–21.
Binbay T, Direk N, Aker T, et al. Psychiatric epidemiology in Turkey: main advances in recent studies and future directions. Turk Psikiyatr Derg, 2014;25(4).
Gurvit H, Emre M, Tinaz S, et al. The prevalence of dementia in an urban Turkish population, Am J Alzheimer’s Dis Other Dementias®. 2008;23(1):67–76.
2020 Alzheimer’s disease facts and figures. Alzheimers Dement, 2020 Mar. Doi: 10.1002/alz.12068
Eratne D, Loi SM, Farrand S, et al. Alzheimer’s disease: clinical update on epidemiology, pathophysiology and diagnosis. Australas Psychiatry, 2018 Aug 1;26(4):347–57.
Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of dementias and Alzheimer’s disease. Arch Med Res, 2012;43(8):600–8.
2016 Alzheimer’s disease facts and figures. Alzheimers Dement, 2016;12: 459–509.
Miyashita A, Koike A, Jun G, et al. SORL1 is genetically associated with late-onset Alzheimer’s disease in Japanese, Koreans and Caucasians. PLoS One, 2013;8(4):e58618.
Silva MVF, Loures C de MG, Alves LCV, et al. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci, 2019;26(1):1–11.
Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol, 2014;88(4):640–51.
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science, 1992;256(5054):184–5.
Gandy S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J Clin Invest, 2005;115(5):1121–9.
Näslund J, Schierhorn A, Hellman U, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci, 1994 Aug 30;91(18):8378–82. doi.org/10.1073/pnas.91.18.8378
Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener, 2006;1(1):1–12.
O’Brien RJ, Wong PC. Amyloid precursor protein processing and alzheimer’s disease. Annu Rev Neurosci, 2011;34:185–204.
Salloway S, Sperling R, Fox NC, et al. Bapineuzumab 301 and 302 Clinical Trial Investigators (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. New England Journal of Medicine, 2014;370(4): 322–33.
J.A. G, Sweet RA. (2017). Neurocognitive Disorders (Dementia). Sadock BJ, Sadock VA, Ruiz P (Ed.), in Comprehensive Textbook of Psychiatry. Lippincott Williams & Wilkins Philadelphia
Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press; 2000.
Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 2019; 179(2):312–39.
Rafii MS, Taylor CS, Kim HT, et al. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer’s disease. Am J Alzheimer’s Dis Other Dementias®, 2014;29(2):159–65.
Schwarz S, Froelich L, Burns A. Pharmacological treatment of dementia. Curr Opin Psychiatry, 2012;25(6):542-550
Campos C, Barbosa N, Rocha F,et al. Treatment of cognıtıve defıcıts ın alzheımer’s dısease: A psychopharmacologıcal review, Psychiatria Danubina, 2016;28(1): 2–12.
McGleenon BM, Dynan KB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer’s disease. Br J Clin Pharmacol, 1999;48(4):471.
Marucci G, Buccioni M, Ben DD, et al. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology, 2021;190:108352. doi:10.1016/j.neuropharm.2020.108352
Vecchio I, Sorrentino L, Paoletti A, et al. The state of the art on acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease. J Cent Nerv Syst Dis, 2021;13:11795735211029112.doi:10.1177/11795735211029113
Miao Y, He N, Zhu J-J. History and new developments of assays for cholinesterase activity and inhibition. Chem Rev, 2010;110(9):5216–34.
Lo D, Grossberg GT. Use of memantine for the treatment of dementia. Expert Rev Neurother [Internet], 2011 Oct 1;11(10):1359–70. doi:10.1586/ern.11.132
Seltzer B. Donepezil: a review. Expert Opin Drug Metab Toxicol, 2005;1(3):527–36.
Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer’s disease: an update. Clin Interv Aging, 2007;2(1):17.
Birks JS, Evans JG. Rivastigmine for Alzheimer’s disease. The Cochrane database of systematic reviews, 2015;(4). doi:10.1002/14651858.
Patel PH, Gupta V. Rivastigmine. In: StatPearls [Internet]. StatPearls Publishing; 2022.
Jann MW. Rivastigmine, a new‐generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacother J Hum Pharmacol Drug Ther, 2000;20(1):1–12.
Williams BR, Nazarians A, Gill MA. A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther, 2003;25(6):1634–53.
Yang LPH, Keating GM. Rivastigmine Transdermal Patch. CNS Drugs, 2007;21(11):957–65.
Galimberti D, Scarpini E. Old and new acetylcholinesterase inhibitors for Alzheimer’s disease.Expert Opin Investig Drugs, 2016;25(10):1181–7.
Prvulovic D, Hampel H, Pantel J. Galantamine for Alzheimer’s disease. Expert opinion on drug metabolism & toxicology, 2010;6(3):345–54.
Seltzer B. Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease, Clinical interventions in aging, 2010;5:1–6.
Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs, 2013;27(6):469–78.
Schmitt F, Ryan M, Cooper G. A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer’s disease. Expert opinion on drug metabolism & toxicology, 2007 Feb 1;3(1):135–41.
Kishi T, Matsunaga S, Oya K, et al. Memantine for Alzheimer’s disease: an updated systematic review and meta-analysis. J Alzheimer’s Dis, 2017;60(2):401–25.
van Marum RJ. Update on the use of memantine in Alzheimer’s disease. Neuropsychiatric disease and treatment, 2009;5:237–47.
Atri A. Current and future treatments in Alzheimer’s disease. Seminars in neurology, 2019;39(2): 227–240;
Kuns B, Rosani A, Varghese D. Memantine. StatPearls. StatPearls Publishing, 2018.
Moussa CEH. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease. Expert opinion on investigational drugs, 2017;26(10):1131–1136.
Zhao J, Liu X, Xia W, et al. Targeting amyloidogenic processing of APP in Alzheimer’s disease. Frontiers in molecular neuroscience, 2020;13:137.
Imbimbo BP, Watling M. Investigational BACE inhibitors for the treatment of Alzheimer’s disease. Expert opinion on investigational drugs, 2019;28(11):967–75.
Panza F, Lozupone M, Solfrizzi V, et al. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease. Expert review of neurotherapeutics, 2018;18(11):847–57.
Wessels AM, Tariot PN, Zimmer JA, et al. Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA neurology, 2020;77(2):199–209.
Odabası MD, Kucukkılınc ZTT. Alzheimer Hastalığı Tedavisindeki Güncel Yaklaşımlar. Hacettepe University Journal of the Faculty of Pharmacy, 41(4):266–80.
Hur J-Y. γ-Secretase in Alzheimer’s disease. Experimental & molecular medicine, 2022;54(4):433–46.
Mangialasche F, Solomon A, Winblad B, et al.Alzheimer’s disease: clinical trials and drug development. The Lancet. Neurology, 2010;9(7):702–16.
Gilman S, Koller M, Black RS, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005;64(9):1553–62.
Li Y, Liu Y, Wang Z, et al. Clinical trials of amyloid-based immunotherapy for Alzheimer’s disease: end of beginning or beginning of end? Expert opinion on biological therapy, 2013;13(11):1515–22.
Mantile F, Prisco A. Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease. Biology, 2020;9(12):425.
Abushouk AI, Elmaraezy A, Aglan A, et al. Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials. BMC neurology, 2017;17(1):66.
Plotkin SS, Cashman NR. Passive immunotherapies targeting Aβ and tau in Alzheimer’s disease. Neurobiology of disease, 2020;144:105010. doi.org/10.1016/j.nbd.2020.105010
Haeberlein SB, Von Hehn C, Tian Y, et al. EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease. San Diego: 12th Clinical Trials on Alzheimer's Disease (2019): 1-25.
Parrocha CMT, Nowick JS. Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease. Peptide Science, 2022;e24289.
Piton M, Hirtz C, Desmetz C, et al. Alzheimer’s disease: advances in drug development. Journal of Alzheimer's disease, 2018;65(1):3–13.
Panza F, Solfrizzi V, Seripa D, et al. Tau-centric targets and drugs in clinical development for the treatment of Alzheimer’s disease. BioMed research international, 2016;2016:3245935. doi.org/10.1155/2016/3245935
Anand K, Sabbagh M. Early investigational drugs targeting tau protein for the treatment of Alzheimer’s disease.Expert opinion on investigational drugs, 2015;24(10):1355–60.
Hoskin JL, Sabbagh MN, Al-Hasan Y,et al. Tau immunotherapies for Alzheimer’s disease. Expert opinion on investigational drugs, 2019;28(6):545–54.
